&lt;p&gt;MicroRNA-145 Inhibits the Activation of the mTOR Signaling Pathway to Suppress the Proliferation and Invasion of Invasive Pituitary Adenoma Cells by Targeting AKT3 in vivo and in vitro [Retraction]&lt;/p&gt;

Purpose Invasive and somatostatin receptor ligands (SRL)-resistant pituitary tumors represent a challenge in the clinical practice of endocrinologists. Efforts have been made to elucidate reliable makers for both. Survivin and eukaryotic translation initiation factor-binding protein 1 (4EBP1) are upregulated in several cancers and involved in apoptosis and cell proliferation. The role of these markers in somatotropinomas remains unclear. Methods Immunostains for survivin and 4EBP1, and also for somatostatin receptor type 2 (SSTR2), Ki-67, and cytokeratin 18 (CK18), were analyzed in tissue microarrays (TMA) containing 52 somatotropinoma samples. Tumor invasiveness was evaluated in all samples while drug-resistance was evaluated in 34 patients who received SRL treatment. All these parameters were correlated with first-generation SRL (fg-SRL) responsiveness and tumor invasiveness. Results Low survivin expression (P = 0.04), hyperintense signal on T2 weighted image (T2WI) (P = 0.01), younger age (P = 0.01), sparsely granular adenomas (SGA) (P = 0.04), high postoperative growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels (P = 0.049 and P < 0.001, respectively), and large postoperative tumor size (P = 0.02) were associated with resistance to fg-SRL. Low survivin and SSTR2 expressions and a high 4EBP1 expression were associated with SGA (P = 0.04, P = 0.01, and P = 0.001, respectively). Younger age (P = 0.03), large tumor -pre and postoperative (P = 0.04 and P = 0.006, respectively), low SSTR2 expression (P = 0.03), and high baseline GH and IGF-1 (P = 0.01 and P = 0.02, respectively) were associated with tumor invasiveness. However, survivin, 4EBP1, Ki-67, and granulation patterns were not associated with tumor invasion. Conclusion This study suggests that low survivin expression is predictive of resistance to fg-SRL in somatotropinomas, but not of tumor invasiveness.

show abstract

Survivin: A Potential Marker of Resistance to Somatostatin Receptor Ligands

Herkenhoff

Trarbach

Batista

et al. 2022

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

<p>MicroRNA-145 Inhibits the Activation of the mTOR Signaling Pathway to Suppress the Proliferation and Invasion of Invasive Pituitary Adenoma Cells by Targeting AKT3 in vivo and in vitro [Retraction]</p>

Cited by 1 publication

References 0 publications

Survivin: A Potential Marker of Resistance to Somatostatin Receptor Ligands

Survivin: A Potential Marker of Resistance to Somatostatin Receptor Ligands

Contact Info

Product

Resources

About